News headlines about ImmunoCellular Therapeutics (NASDAQ:IMUC) have trended somewhat positive on Thursday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ImmunoCellular Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.0134489142722 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Separately, Maxim Group reissued a “hold” rating on shares of ImmunoCellular Therapeutics in a research report on Thursday, August 24th.

ImmunoCellular Therapeutics (NASDAQ:IMUC) traded up 3.5803% during trading on Thursday, hitting $0.3761. The stock had a trading volume of 12,348,396 shares. The company’s market cap is $5.96 million. ImmunoCellular Therapeutics has a 12 month low of $0.25 and a 12 month high of $4.80. The company’s 50 day moving average is $0.33 and its 200-day moving average is $1.17.

TRADEMARK VIOLATION NOTICE: “ImmunoCellular Therapeutics (IMUC) Receiving Somewhat Favorable Press Coverage, Analysis Finds” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/05/immunocellular-therapeutics-imuc-receiving-somewhat-favorable-press-coverage-analysis-finds.html.

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Stock Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related stocks with our FREE daily email newsletter.